<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Cancer</journal-id><journal-title>Molecular Cancer</journal-title><issn pub-type="epub">1476-4598</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19228372</article-id><article-id pub-id-type="pmc">2647895</article-id><article-id pub-id-type="publisher-id">1476-4598-8-9</article-id><article-id pub-id-type="doi">10.1186/1476-4598-8-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Protein kinase C&#x003b5;: an oncogene and emerging tumor biomarker</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Gorin</surname><given-names>Michael A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>magorin@med.miami.edu</email></contrib><contrib id="A2" corresp="yes" contrib-type="author"><name><surname>Pan</surname><given-names>Quintin</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>quintin.pan@osumc.edu</email></contrib></contrib-group><aff id="I1"><label>1</label>University of Miami, Miller School of Medicine, Miami, FL 33136, USA</aff><aff id="I2"><label>2</label>Department of Otolaryngology-Head and Neck Surgery, the Ohio State University Medical Center, Columbus, OH 43210, USA</aff><aff id="I3"><label>3</label>Arthur G James Cancer Hospital and Richard J Solove Research Institute, the Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>19</day><month>2</month><year>2009</year></pub-date><volume>8</volume><fpage>9</fpage><lpage>9</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molecular-cancer.com/content/8/1/9"/><history><date date-type="received"><day>6</day><month>11</month><year>2008</year></date><date date-type="accepted"><day>19</day><month>2</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Gorin and Pan; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Gorin and Pan; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>               Gorin               A               Michael                              magorin@med.miami.edu            </dc:author><dc:title>            Protein kinase C&#x003b5;: an oncogene and emerging tumor biomarker         </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>Molecular Cancer 8(1): 9-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1476-4598(2009)8:1&#x0003c;9&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1476-4598</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><p>Members of the protein kinase C (PKC) family have long been studied for their contributions to oncogenesis. Among the ten different isoforms of this family of serine/threonine kinases, protein kinase C&#x003b5; (PKC&#x003b5;) is one of the best understood for its role as a transforming oncogene. <italic>In vitro</italic>, overexpression of PKC&#x003b5; has been demonstrated to increase proliferation, motility, and invasion of fibroblasts or immortalized epithelial cells. In addition, xenograft and transgenic animal models have clearly shown that overexpression of PKC&#x003b5; is tumorigenic resulting in metastatic disease. Perhaps most important in implicating the epsilon isoform in oncogenesis, PKC&#x003b5; has been found to be overexpressed in tumor-derived cell lines and histopathological tumor specimens from various organ sites. Combined, this body of work provides substantial evidence implicating PKC&#x003b5; as a transforming oncogene that plays a crucial role in establishing an aggressive metastatic phenotype. Reviewed here is the literature that has led to the current understanding of PKC&#x003b5; as an oncogene. Moreover, this review focuses on the PKC&#x003b5;-mediated signaling network for cell motility and explores the interaction of PKC&#x003b5; with three major PKC&#x003b5; signaling nodes: RhoA/C, Stat3 and Akt. Lastly, the emerging role of PKC&#x003b5; as a tumor biomarker is discussed.</p></abstract></article-meta></front><body><sec><title>Introduction to the protein kinase C (PKC) family</title><p>Several decades of research have documented that members of the protein kinase C (PKC) family of serine/threonine kinases are key signaling molecules involved in diverse cellular functions. Comprised of ten different isoforms, the PKC family is divided into three groups according to structural features and activation requirements. The classical isoforms (&#x003b1;, &#x003b2;I, &#x003b2;II, and &#x003b3;) have an intact C1 diacylglycerol/phorbol ester binding domain and C2 calcium binding domain and thus require phospholipids and calcium for activation. The second group contains the novel isoforms (&#x003b4;, &#x003b5;, &#x003b8;, and &#x003b7;,), which do not require calcium for their activation. The third group contains the atypical isoforms (&#x003b6;, and &#x003b9;/&#x003bb;), which can be activated in the absence of diacyglycerol and calcium.</p><p>Some of the many cellular processes regulated by PKCs include apoptosis, proliferation, migration, motility, chemo-resistance and differentiation (reviewed in [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B4">4</xref>]). Most notably, PKCs have been extensively studied in the context of oncogenesis. This body of literature first arose from work done in the 1980s when PKC was identified as an intracellular receptor for the tumor promoting phorbol esters [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. Since these early reports, the discrete roles of many PKC isoforms in oncogenesis have been studied. It is now appreciated that each of the ten PKC isoforms is unique in its contribution to cancer development and progression. For example, within the context of an animal model of skin cancer, overexpression of PKC&#x003b1; has no effect on tumorigenesis [<xref ref-type="bibr" rid="B8">8</xref>], while the delta isoform suppresses tumor development [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. In contrast, the epsilon isoform is severely oncogenic and promotes metastatic squamous cell carcinoma [<xref ref-type="bibr" rid="B10">10</xref>]. In other model systems, the varying roles of PKC isoforms have also been documented. PKC&#x003b1; has been described as an essential pro-proliferative and survival molecule in glioma cell lines [<xref ref-type="bibr" rid="B11">11</xref>]. Recently, PKC&#x003b1; was reported as a mediator of cell proliferation in head and neck cancer cell lines and as a predictive biomarker for disease-free survival in head and neck cancer patients [<xref ref-type="bibr" rid="B12">12</xref>]. Similarly, the iota isoform is now appreciated for its role in promoting cell motility/invasion [<xref ref-type="bibr" rid="B13">13</xref>] and proliferation [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>Among the many PKC family members, several isoforms have been found to have paradoxical and tissue specific roles in tumor initiation. Of note, the contribution of PKC&#x003b4; to oncogenesis has been contested through conflicting experimental findings. For example, several lines of evidence support PKC&#x003b4; as an anti-proliferative molecule. These data include the work done in animal models of skin cancer [<xref ref-type="bibr" rid="B9">9</xref>] as well as the finding that PKC&#x003b4; expression can revert transformed rat colonic epithelial cells towards a wild-type phenotype [<xref ref-type="bibr" rid="B15">15</xref>]. In contrast to this body of work, others have found that PKC&#x003b4; promotes the survival of breast and lung cancer cells [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. This discrepancy speaks to the complexity of understanding the roles of PKC family members in the context of oncogenesis. From the abundant literature on PKCs, it is clear that the function of PKC isoforms in oncogenesis is highly tissue dependent and thus it is critical to understand the role of each PKC isoform in the proper cellular context.</p></sec><sec><title>PKC&#x003b5; as a transforming oncogene</title><p>In one of the first experimental works aimed specifically at exploring the oncogenic potential of PKC&#x003b5;, Mischak and colleagues overexpressed PKC&#x003b5; in NIH 3T3 fibroblasts [<xref ref-type="bibr" rid="B18">18</xref>]. These authors found that upon PKC&#x003b5; overexpression, cells grew at a faster rate and with increased densities and confluence. Cells transfected with PKC&#x003b5; also demonstrated an increased ability to grow in soft agar in the absence of phorbol 12-myristate 13-acetate (PMA). <italic>In vivo</italic>, 100% of mice injected with PKC&#x003b5; overexpressing NIH 3T3 cells developed tumors. Mice injected with PKC&#x003b4;-expressing or untransfected NIH 3T3 cells did not develop tumors. Combined, these findings were among the first evidence demonstrating PKC&#x003b5; as an oncogene.</p><p>In the same year, Cacace and coworkers found that overexpression of PKC&#x003b5; in fibroblasts leads to an oncogenic phenotype <italic>in vitro </italic>and <italic>in vivo </italic>[<xref ref-type="bibr" rid="B19">19</xref>]. Similar to these earlier findings, Perletti <italic>et al</italic>. found that overexpression PKC&#x003b5; in FRC/TEX CL D (D/WT) colonic epithelial cells led to a metastatic phenotype which included morphological changes, increased anchorage independent growth and marked tumorigenesis in a xenograft model [<xref ref-type="bibr" rid="B20">20</xref>]. These reports set the stage for our current understanding of PKC&#x003b5; as a transforming oncogene.</p></sec><sec><title>Proliferation and cell survival</title><p>Many of the details about the pro-tumorigenic signaling pathways modulated by PKC&#x003b5; have been elucidated. For example, PKC&#x003b5; is known to exert its oncogenic effects through modulation of the Ras signaling cascade [<xref ref-type="bibr" rid="B21">21</xref>-<xref ref-type="bibr" rid="B24">24</xref>], one of the best characterized signaling pathways in all of cancer biology (reviewed in [<xref ref-type="bibr" rid="B25">25</xref>]). Among the many downstream effects of Ras signaling includes increased cell cycling via up-regulation of cyclin D1 [<xref ref-type="bibr" rid="B26">26</xref>-<xref ref-type="bibr" rid="B29">29</xref>]. PKC&#x003b5; expression has been linked to activation of the cyclin D1 promoter and increased growth rates [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>]</p><p>In addition to its influence on Ras signaling, PKC&#x003b5; has also been implicated in anti-apoptotic signaling pathways through the modulation of caspases and Bcl-2 family members [<xref ref-type="bibr" rid="B32">32</xref>-<xref ref-type="bibr" rid="B38">38</xref>]. Similarly, PKC&#x003b5; exerts its pro-survival effects by activating Akt/PKB [<xref ref-type="bibr" rid="B39">39</xref>-<xref ref-type="bibr" rid="B41">41</xref>]. Like the Ras signaling pathway, the pro-proliferative effects of Akt signaling are well described in the context of oncogenesis (reviewed in [<xref ref-type="bibr" rid="B42">42</xref>]). The role of PKC&#x003b5; in proliferation and survival signaling pathways has been extensively reviewed by Basu and Sivaprasad [<xref ref-type="bibr" rid="B43">43</xref>].</p></sec><sec><title>Motility and invasion</title><p>In addition to promotion of proliferation and escape from apoptosis, dysregulation of cellular adhesion and motility are key components of a metastatic phenotype. The ability of a cell to migrate is essential for invasion of surrounding tissues as well as spread to distal sites. It is now appreciated that overexpression of PKC&#x003b5; leads to a highly motile and invasive phenotype. For example, Tachado and coworkers reported that expression of PKC&#x003b5; promotes a polarized cell morphology and <italic>in vitro </italic>cell invasion [<xref ref-type="bibr" rid="B44">44</xref>]. Moreover, these authors found that mice inoculated with NIH 3T3 cells overexpressing PKC&#x003b5; experienced tumor invasion of nearby tissues as well as liver metastases. Consistent with these findings, our group demonstrated that knockdown of PKC&#x003b5; with RNAi decreases <italic>in vitro </italic>invasion and motility [<xref ref-type="bibr" rid="B45">45</xref>,<xref ref-type="bibr" rid="B46">46</xref>], as well as incidence of lung metastases in a pre-clinical animal model of breast cancer [<xref ref-type="bibr" rid="B45">45</xref>].</p><p>Specific details of how PKC&#x003b5; modulates cell motility are beginning to emerge. It is now known that PKC&#x003b5; contains an actin binding domain [<xref ref-type="bibr" rid="B47">47</xref>]. Motile cells overexpressing PKC&#x003b5; have been observed to extend lamepidia-like protrusions [<xref ref-type="bibr" rid="B44">44</xref>]. The ability of PKC&#x003b5; to promote F-actin assembly in a cell-free system is compelling evidence for the role of PKC&#x003b5; in modulating outgrowth through actin polymerization [<xref ref-type="bibr" rid="B48">48</xref>]. PKC&#x003b5; has been observed to translocate to the cell membrane during the formation of focal adhesions [<xref ref-type="bibr" rid="B49">49</xref>]. This initial process of cellular adhesion to the extracellular matrix is known as cell spreading. During spreading, a cell undergoes a redistribution of adhesion and structural molecules. Once a cell has spread it may then take part in contact dependent functions such as motility. The expression of &#x003b2;1-integrin cytoplasmic domain connected to a non-signaling transmembrane domain inhibits the process of cell spreading [<xref ref-type="bibr" rid="B50">50</xref>]. PKC&#x003b5; is sufficient to rescue cell spreading in cells expressing non-signaling &#x003b2;1-integrin molecules [<xref ref-type="bibr" rid="B50">50</xref>]. This finding suggests PKC&#x003b5; signaling downstream of &#x003b2;1-integrin engagement with the extracellular matrix.</p><p>Ivaska <italic>et al</italic>. reported that PKC&#x003b5; plays a role in the return of endocytosed &#x003b2;1-integrin molecules to the plasma membrane [<xref ref-type="bibr" rid="B51">51</xref>]. The inhibition of PKC&#x003b5; with bisindolylmaleimide I (BIM-I) leads to an accumulation of intercellular &#x003b2;1-integrin/PKC&#x003b5; containing vesicles. Without the recycling of integrins, a necessary process for the advancement of cell's leading edge, a decrease in motility was observed. It is now known that phosphorylation of the cytoskeletal protein, vimentin, by PKC&#x003b5; is needed for the regulated release of integrin from recycled vesicles back to the plasma membrane [<xref ref-type="bibr" rid="B52">52</xref>].</p><p>In glioma cells, PKC&#x003b5; has also been found to be an important promoter of cell migration [<xref ref-type="bibr" rid="B53">53</xref>,<xref ref-type="bibr" rid="B54">54</xref>]. In adhesion assays, PKC&#x003b5; overexpressing cells were shown to adhere in greater numbers to laminin, vitronectin and fibronectin as compared to control cells [<xref ref-type="bibr" rid="B54">54</xref>]. PKC&#x003b5; expression was also responsible for lamellipodia formation. Similar to other reports, these authors found that PKC&#x003b5; interacts with &#x003b2;-integrin chains. In addition, it was found that RACK1, a scaffold protein associated with PKC&#x003b5;, is also a requirement of cell motility and forms a complex along with PKC&#x003b5; and &#x003b2;-integrin. This same group also found that extracellular-signal related kinase (ERK) localizes to sites of focal adhesions [<xref ref-type="bibr" rid="B53">53</xref>]. In PKC&#x003b5; overexpressing clones, an increase in the amount of activated phospho-ERK, a downstream molecule in the Ras signaling cascade, was observed. Cells transfected with an anti-sense PKC&#x003b5; cDNA showed the opposite pattern. Moreover, upon inhibition of the ERK signaling pathway, cells were less adhesive and motile in response to PMA stimulation.</p><p>Our laboratory reported that PKC&#x003b5;-driven cell motility is mediated at least in part due to downstream activation of small Rho GTPases, specifically RhoA and/or RhoC [<xref ref-type="bibr" rid="B45">45</xref>,<xref ref-type="bibr" rid="B46">46</xref>]. RNAi-mediated knockdown of PKC&#x003b5; in head and neck cancer cells with elevated endogenous PKC&#x003b5; levels is sufficient to significantly impair cell motility [<xref ref-type="bibr" rid="B46">46</xref>]. Moreover, reconstitution of constitutive active RhoA or RhoC in these PKC&#x003b5;-deficient head and neck cancer cells rescued the loss-of-function motility defect providing direct evidence that RhoA and RhoC is downstream of the PKC&#x003b5; signaling cascade [<xref ref-type="bibr" rid="B46">46</xref>]. Our work, although novel, merely adds to the published literature on the linear signaling pathways mediated by PKC&#x003b5; to modulate cell motility. It is clear that signal transduction pathways must be approached through a systems biology perspective to capture the conditions necessary to drive a particular cellular event. To this end, we constructed a schematic model of the PKC&#x003b5; signaling network for cell motility using published results from our laboratory and other laboratories (Figure <xref ref-type="fig" rid="F1">1</xref>). This model contains three highly interconnected PKC&#x003b5; signaling nodes, Akt, RhoA/RhoC, and Stat3, with multiple positive and negative points.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Schematic model illustrating the PKC&#x003b5; signaling network for cell motility</bold>. Arrow Black lines represent activation and Circle red lines represent inactivation. Arrow dashed lines represent putative interactions based on <italic>in silico </italic>transcription factor binding prediction software. All interactions are based on published literature as described in the text.</p></caption><graphic xlink:href="1476-4598-8-9-1"/></fig><p>Akt is activated through two phosphorylation events. PDK1 phosphorylates Akt at threonine 308 and recently, PKC&#x003b5; was identified as the kinase that phosphorylates Akt at serine 473 leading to full Akt activation [<xref ref-type="bibr" rid="B55">55</xref>]. There is evidence that Akt phosphorylates and activates PAK1 to enhance cell migration [<xref ref-type="bibr" rid="B56">56</xref>,<xref ref-type="bibr" rid="B57">57</xref>]. Interestingly, PAK1 was shown to inhibit the activity of NET1, a RhoA-specific guanine nucleotide exchange factor, suggesting that PAK1 will inhibit RhoA activation under certain conditions [<xref ref-type="bibr" rid="B58">58</xref>]. PAK1 phosphorylates myosin light chain kinase (MLCK) resulting in decreased MLCK activity and myosin light chain (MLC) phosphorylation in epithelial cells [<xref ref-type="bibr" rid="B59">59</xref>]. MLC is a component of myosin and involved in the assembly of actomyosin filaments for contraction. MLC is phosphorylated at Ser19 by myosin light chain kinase (MLCK) and Rho-kinase, a downstream effecter of RhoA and RhoC, to enhance myosin ATPase activity and muscle contraction [<xref ref-type="bibr" rid="B60">60</xref>,<xref ref-type="bibr" rid="B61">61</xref>]. PAK1 and Rho-kinase also directly regulates the activation of LIM domain kinases (LIMKs), a family of two serine/threonine kinases involved in actin cytoskeleton regulation. PAK1 phosphorylates LIMK1 at Thr508 and Rho-kinase, a downstream effector of RhoA and RhoC, phosphorylates LIMK2 at Thr505 resulting in an increase in LIMK1 and LIMK2 activity, respectively [<xref ref-type="bibr" rid="B62">62</xref>,<xref ref-type="bibr" rid="B63">63</xref>]. Activated LIMK1/LIMK2 inhibits the actin depolymerizing activity of cofilin by phosphorylation at the Ser3 residue of cofilin resulting in formation of stress fibers and focal adhesions for cell migration [<xref ref-type="bibr" rid="B63">63</xref>-<xref ref-type="bibr" rid="B65">65</xref>].</p><p>Recent reports demonstrated that PKC&#x003b5; directly phosphorylates Stat3 at Ser727 resulting in an increase in nuclear translocation and transcriptional activation of Stat3 [<xref ref-type="bibr" rid="B66">66</xref>-<xref ref-type="bibr" rid="B68">68</xref>]. Additionally, RhoA activation, mediated at least in part through Rho-kinase, results in an increase in Stat3 phosphorylation at Tyr705 and Ser727 and nuclear translocation [<xref ref-type="bibr" rid="B69">69</xref>]. Interestingly, Stat3 was reported to directly bind to the tubulin-binding region of stathmin to attenuate binding of stathmin to tubulin resulting in microtubule stabilization [<xref ref-type="bibr" rid="B70">70</xref>]. Stathmin is a ubiquitous cytosolic phosphoprotein involved in the regulation of the microtubule filament system by promoting tubulin filament depolymerization. Stathmin was reported to be phosphorylated at four serine residue, Ser16, Ser25, Ser38, and Ser63 by various kinases, including cyclin-dependent kinase, MAP kinase, and PKA [<xref ref-type="bibr" rid="B71">71</xref>,<xref ref-type="bibr" rid="B72">72</xref>]. Phosphorylation of stathmin at Ser16 and Ser63 was found to be necessary to optimally prevent stathmin from binding to tubulin resulting in microtubule stabilization [<xref ref-type="bibr" rid="B73">73</xref>].</p><p><italic>In silico </italic>analysis using the Genomatix-MatInspector software identified Stat3 and serum response factor (SRF) transcription factor binding sites in the predicted PKC&#x003b5; promoter region. Stat3 nuclear translocation and transcriptional activity are regulated directly by PKC&#x003b5; and Rho-kinase [<xref ref-type="bibr" rid="B68">68</xref>]. In addition, SRF-mediated transcription is activated in response to RhoA and RhoC activation [<xref ref-type="bibr" rid="B74">74</xref>,<xref ref-type="bibr" rid="B75">75</xref>]. These observations is attractive from a molecular mechanism point of view as it suggests that a feed-forward mechanism, through PKC&#x003b5;-mediated increases in Stat3 and SRF transcriptional activities, may result in a sustained activation of the PKC&#x003b5; signaling network. Moreover, it is not known at this time, the contribution and requirement of each PKC&#x003b5; signaling module for promoting a motile cell phenotype. It is possible that there is redundancy in this system and that perhaps, only select nodes are indispensable to drive PKC&#x003b5;-mediated cell motility in cancer cells.</p></sec><sec><title>Overexpression in various cancer types</title><p>The role PKC&#x003b5; in specific cancer types has been explored in great detail. To date, the overexpression of PKC&#x003b5; has been observed in a large number of cancer types (Table <xref ref-type="table" rid="T1">1</xref>). The etiology of PKC&#x003b5; overexpression, however, remains elusive. To the best of our knowledge, no publications exist which document mutations responsible for PKC&#x003b5; overexpression. One group, however, has found 2p21 to be amplified in the rearranged DNA of WRO thyroid carcinoma cell lines and thyroid tumor samples [<xref ref-type="bibr" rid="B76">76</xref>,<xref ref-type="bibr" rid="B77">77</xref>]. This region on the short arm of chromosome 2 is home to the PKC&#x003b5; gene. The clinical value of this knowledge, however, is yet to be determined. Regardless of the origin of PKC&#x003b5; overexpression, it is clear that this protein is emerging through the literature as an important biomarker and potential drug target for many cancer types.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>PKC&#x003b5; overexpression in histopathological specimens</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Organ</bold></td><td align="left"><bold>Reference</bold></td></tr></thead><tbody><tr><td align="left">Bladder</td><td align="left">84</td></tr><tr><td align="left">Brain</td><td align="left">87</td></tr><tr><td align="left">Breast</td><td align="left">45</td></tr><tr><td align="left">Head and Neck</td><td align="left">78</td></tr><tr><td align="left">Lung</td><td align="left">80</td></tr><tr><td align="left">Prostate</td><td align="left">67, 82</td></tr></tbody></table></table-wrap><p>Our laboratory was the first to report that PKC&#x003b5; plays a causative role in establishing an aggressive, invasive, and motile phenotype in breast cancer [<xref ref-type="bibr" rid="B45">45</xref>]. Inhibition of PKC&#x003b5; by RNAi in MDA-MB231 cells, a highly metastatic breast cancer cell line with elevated PKC&#x003b5; levels, was sufficient to dramatically decrease cell proliferation, anchorage-independent colony formation, invasion, and motility <italic>in vitro</italic>. Similarly, MDA-MB231 cells transfected with RNAi against PKC&#x003b5; showed decreased tumor growth kinetics and a reduced incidence in the number of lung metastases in an orthotopic model of breast cancer. Moreover, using high-density tissue microarrays with tumor specimens from invasive ductal breast carcinoma patients, elevated PKC&#x003b5; was associated with high histologic grade, positive Her2/neu receptor status, and negative estrogen and progesterone receptor status. In addition, elevated PKC&#x003b5; was demonstrated to be a prognostic biomarker of poorer overall and disease-free survival.</p><p>PKC&#x003b5; has also been implicated in head and neck squamous cell carcinoma (HNSCC). In a small prospective study of 29 patients with primary squamous cell carcinomas of the oral cavity, elevated PKC&#x003b5; levels were significantly associated with disease relapse and decreased overall survival [<xref ref-type="bibr" rid="B78">78</xref>]. The authors of this study concluded that elevated PKC&#x003b5; may serve as a prognostic marker of aggressive disease in oral cancers. Consistent with this work, our laboratory reported that PKC&#x003b5; is elevated in a panel of HNSCC cell lines [<xref ref-type="bibr" rid="B46">46</xref>]. <italic>In vitro</italic>, HNSCC cell lines with high endogenous PKC&#x003b5; levels are associated with a highly invasive and motile phenotype. Additionally, RNAi-mediated silencing of PKC&#x003b5; in HNSCC with high endogenous PKC&#x003b5; levels resulted in a marked reduction in cell invasion and motility.</p><p>Elevated levels of PKC&#x003b5; have been documented in lung cancers. In the small cell lung carcinoma cell line (SCLC) NCI-N417, a constitutively active catalytic fragment of PKC&#x003b5; has been reported [<xref ref-type="bibr" rid="B79">79</xref>]. In non-SCLC cell lines (NSCLC), PKC&#x003b5; is associated with a chemo-resistant phenotype [<xref ref-type="bibr" rid="B32">32</xref>]. Aberrant PKC&#x003b5; levels have also been observed in histopathological lung tumor specimens [<xref ref-type="bibr" rid="B80">80</xref>]. Bae and colleagues have found PKC&#x003b5; to be overexpressed in &#x0003e;90% of NSCLC histological sections as compared to normal controls.</p><p>Like our group's work in both breast and head and neck cancer, inhibition of PKC&#x003b5; in NSCLC cells leads to decreased aggressive phenotype <italic>in vitro </italic>[<xref ref-type="bibr" rid="B80">80</xref>]. More specifically, cells treated with a dominant negative version of PKC&#x003b5; showed marked decreases in cell proliferation and anchorage-independent growth. Treatment of NSCLC cells with this dominant negative, or a RNAi against PKC&#x003b5;, resulted in a decrease in G<sub>1</sub>-S cell cycle transition. The authors attribute this arrest to an induction of p21/Cip1, a cyclin-dependent kinase inhibitor. From these results the authors point to PKC&#x003b5; as promoting dysregulation of the cell cycle in NSCLC.</p><p>In an animal model of prostate cancer, overexpression of PKC&#x003b5; in androgen-dependent LNCaP cells resulted in a transformation to an androgen-independent phenotype [<xref ref-type="bibr" rid="B81">81</xref>]. In both wild-type and castrated male nude mice, these cells undergo aggressive tumor growth. <italic>In vitro</italic>, PKC&#x003b5; overexpression conferred an increase in proliferation as well as resistance to apoptosis. Elevated PKC&#x003b5; levels have also been documented in clinical prostate cancer samples. One investigation found PKC&#x003b5; to be overexpressed in specimens of early prostatic adenocarcinomas obtained at time of radical prostatectomy [<xref ref-type="bibr" rid="B82">82</xref>]. As determined by high-density tissue microarrays, other investigators found increasing PKC&#x003b5; levels to correlate with tumor grade [<xref ref-type="bibr" rid="B67">67</xref>]. PKC&#x003b5; has also been found to be overexpressed in samples from other tissues of the urogenital tract. High PKC&#x003b5; levels have been detected in renal carcinoma cells [<xref ref-type="bibr" rid="B83">83</xref>] and in tumor specimens from the urinary bladder [<xref ref-type="bibr" rid="B84">84</xref>]. In the latter, increasing PKC&#x003b5; cells correlated with tumor grade [<xref ref-type="bibr" rid="B84">84</xref>].</p><p>PKC&#x003b5; has been shown to be an important player in driving squamous cell carcinoma (SCC) of the skin. Transgenic expression of PKC&#x003b5; under the control of the human keratin 14 promoter/enhancer has been shown to result in an 18-fold increase in PKC&#x003b5; [<xref ref-type="bibr" rid="B11">11</xref>]. This overexpression of PKC&#x003b5; drove the development of SSC in these animals with 40% of transgenic mice developing SSC of the skin as compared to 7% of controls. Histopathology revealed malignant invasion of tumors as well as metastases to regional lymph nodes. Overexpression of PKC&#x003b5; in FVB/N mice has also been demonstrated to predispose mice to SCC after ultra-violate radiation (UVR) exposure [<xref ref-type="bibr" rid="B85">85</xref>].</p><p>PKC&#x003b5; has been studied in malignancies of the central nervous system. In glioblastoma cell cultures, PKC&#x003b5; was found to be elevated between three to thirty times that of normal protein levels [<xref ref-type="bibr" rid="B86">86</xref>]. Consistent with this observation, Sharif and Sharif have reported that PKC&#x003b5; is overexpressed in a large number of astroglial cell lines [<xref ref-type="bibr" rid="B87">87</xref>]. Similarly, these authors report that PKC&#x003b5; is overexpressed in histological samples from anaplastic astrocytoma, globlastoma multiforme and gliosarcoma tumor samples. Interestingly, PKC&#x003b5; was not found in polocytic astrocytomas samples, a grade I malignancy.</p><p>The role or PKC&#x003b5; in myelo- and lympho- proliferative diseases has not been well studied. In one animal model, overexpression of PKC&#x003b5; in the epidermis of mice results in a myeloproliferative disease characterized by gross increases in the number eiosiniphils and neutrophils [<xref ref-type="bibr" rid="B88">88</xref>]. These mice show marked increases in serum levels of interleukin-5, interleukin-6 and G-CSF as well as infiltration of the lungs, liver and kidneys by the proliferative myeloid cells. The authors postulate that the overexpression of PKC&#x003b5; in these mice leads to an induction of cytokines which in turn promotes disease. Although this model system may prove to be important in studying myeloproliferative disease, the clinical significance of PKC&#x003b5; in this setting is still uncertain. At present, there is no existing literature to document PKC&#x003b5; overexpression in samples from patients with hematopoetic cancers. As such, the role of PKC&#x003b5; in such diseases of the hematopoetic compartment is unclear.</p></sec><sec><title>Conclusion</title><p>Dysregulation of PKC&#x003b5; is a frequent genetic event associated with oncogenesis from multiple organ sites, including breast, prostate, and head and neck. PKC&#x003b5; is elevated in cell lines derived from patients and primary tumor specimens in numerous cancers providing substantial evidence for PKC&#x003b5; as a general transforming oncogene. Evidence to support PKC&#x003b5; as a prognostic biomarker for disease-recurrence and overall survival is beginning to emerge. Additional work is needed before the utility of PKC&#x003b5; as a value-added tool in the clinical decision-making process can be applied in the clinic. There is accumulating literature on the PKC&#x003b5; signaling pathway involved for cell invasion, motility, proliferation and survival; however, a system biology approach will be needed to begin to understand the conditions necessary to drive PKC&#x003b5;-mediated oncogenesis. Detailed understanding of the global PKC&#x003b5; signaling network, including temporal and intensity dynamics, is essential to identify "druggable" points in the signaling cascade to optimize therapeutic efficacy and minimize unwanted adverse effects. This approach will lead to the development of novel molecularly-targeted anti-cancer therapeutics which hopefully will improve the prognosis or quality of life for patients with aggressive metastatic disease.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>MAG and QP drafted the manuscript. All authors read and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We apologize to the researchers whose findings were not covered in this Review due to space limitations. This work was supported by grants from the American Cancer Society, the Flight Attendant Medical Research Institute, and the National Institutes of Health/National Cancer Institute (R01-CA135096 and P50-CA097248).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jaken</surname><given-names>S</given-names></name></person-group><article-title>Protein kinase C isozymes and substrates</article-title><source>Curr Opin Cell Biol</source><year>1996</year><volume>8</volume><fpage>168</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">8791416</pub-id><pub-id pub-id-type="doi">10.1016/S0955-0674(96)80062-7</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dempsey</surname><given-names>EC</given-names></name><name><surname>Newton</surname><given-names>AC</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name><name><surname>Fields</surname><given-names>AP</given-names></name><name><surname>Reyland</surname><given-names>ME</given-names></name><name><surname>Insel</surname><given-names>PA</given-names></name><name><surname>Messing</surname><given-names>RO</given-names></name></person-group><article-title>Protein kinase C isozymes and the regulation of diverse cell responses</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2000</year><volume>279</volume><fpage>L429</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">10956616</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gutcher</surname><given-names>I</given-names></name><name><surname>Webb</surname><given-names>PR</given-names></name><name><surname>Anderson</surname><given-names>NG</given-names></name></person-group><article-title>The isoform-specific regulation of apoptosis by protein kinase C</article-title><source>Cell Mol Life Sci</source><year>2003</year><volume>60</volume><fpage>1061</fpage><lpage>1070</lpage><pub-id pub-id-type="pmid">12861375</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Griner</surname><given-names>EM</given-names></name><name><surname>Kazanietz</surname><given-names>MG</given-names></name></person-group><article-title>Protein kinase C and other diacylglycerol effectors in cancer</article-title><source>Nat Rev Cancer</source><year>2007</year><volume>7</volume><fpage>281</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">17384583</pub-id><pub-id pub-id-type="doi">10.1038/nrc2110</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Castagna</surname><given-names>M</given-names></name><name><surname>Takai</surname><given-names>Y</given-names></name><name><surname>Kaibuchi</surname><given-names>K</given-names></name><name><surname>Sano</surname><given-names>K</given-names></name><name><surname>Kikkawa</surname><given-names>U</given-names></name><name><surname>Nishizuka</surname><given-names>Y</given-names></name></person-group><article-title>Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters</article-title><source>J Biol Chem</source><year>1982</year><volume>257</volume><fpage>7847</fpage><lpage>7851</lpage><pub-id pub-id-type="pmid">7085651</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kikkawa</surname><given-names>U</given-names></name><name><surname>Takai</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Miyake</surname><given-names>R</given-names></name><name><surname>Nishizuka</surname><given-names>Y</given-names></name></person-group><article-title>Protein kinase C as a possible receptor protein of tumor-promoting phorbol esters</article-title><source>J Biol Chem</source><year>1983</year><volume>258</volume><fpage>11442</fpage><lpage>11445</lpage><pub-id pub-id-type="pmid">6311812</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leach</surname><given-names>KL</given-names></name><name><surname>James</surname><given-names>ML</given-names></name><name><surname>Blumberg</surname><given-names>PM</given-names></name></person-group><article-title>Characterization of a specific phorbol ester aporeceptor in mouse brain cytosol</article-title><source>Proc Natl Acad Sci USA</source><year>1983</year><volume>80</volume><fpage>4208</fpage><lpage>4212</lpage><pub-id pub-id-type="pmid">6308606</pub-id><pub-id pub-id-type="doi">10.1073/pnas.80.14.4208</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>AP</given-names></name><name><surname>Dreckschmidt</surname><given-names>NE</given-names></name><name><surname>Verwiebe</surname><given-names>EG</given-names></name><name><surname>Wheeler</surname><given-names>DL</given-names></name><name><surname>Oberley</surname><given-names>TD</given-names></name><name><surname>Verma</surname><given-names>AK</given-names></name></person-group><article-title>Relation of the induction of epidermal ornithine decarboxylase and hyperplasia to the different skin tumor-promotion susceptibilities of protein kinase C alpha, -delta and -epsilon transgenic mice</article-title><source>Int J Cancer</source><year>2001</year><volume>93</volume><fpage>635</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">11477572</pub-id><pub-id pub-id-type="doi">10.1002/ijc.1395</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reddig</surname><given-names>PJ</given-names></name><name><surname>Dreckschmidt</surname><given-names>NE</given-names></name><name><surname>Ahrens</surname><given-names>H</given-names></name><name><surname>Simsiman</surname><given-names>R</given-names></name><name><surname>Tseng</surname><given-names>CP</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Oberley</surname><given-names>TD</given-names></name><name><surname>Verma</surname><given-names>AK</given-names></name></person-group><article-title>Transgenic mice overexpressing protein kinase Cdelta in the epidermis are resistant to skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><fpage>5710</fpage><lpage>5718</lpage><pub-id pub-id-type="pmid">10582689</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>AP</given-names></name><name><surname>Verwiebe</surname><given-names>EG</given-names></name><name><surname>Dreckschmidt</surname><given-names>NE</given-names></name><name><surname>Wheeler</surname><given-names>DL</given-names></name><name><surname>Oberley</surname><given-names>TD</given-names></name><name><surname>Verma</surname><given-names>AK</given-names></name></person-group><article-title>Protein kinase C-epsilon transgenic mice: a unique model for metastatic squamous cell carcinoma</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>808</fpage><lpage>812</lpage><pub-id pub-id-type="pmid">11221859</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>AJ</given-names></name><name><surname>Procyk</surname><given-names>KJ</given-names></name><name><surname>Leitges</surname><given-names>M</given-names></name><name><surname>Parker</surname><given-names>PJ</given-names></name></person-group><article-title>PKC alpha protein but not kinase activity is critical for glioma cell proliferation and survival</article-title><source>Int J Cancer</source><year>2008</year><volume>123</volume><fpage>769</fpage><lpage>779</lpage><pub-id pub-id-type="pmid">18508315</pub-id><pub-id pub-id-type="doi">10.1002/ijc.23560</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>EE</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Lingen</surname><given-names>MW</given-names></name><name><surname>Martin</surname><given-names>LE</given-names></name><name><surname>Kuo</surname><given-names>WL</given-names></name><name><surname>Choi</surname><given-names>EA</given-names></name><name><surname>Kocherginsky</surname><given-names>M</given-names></name><name><surname>Parker</surname><given-names>JS</given-names></name><name><surname>Chung</surname><given-names>CH</given-names></name><name><surname>Rosner</surname><given-names>MR</given-names></name></person-group><article-title>A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">19117988</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-0377</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baldwin</surname><given-names>RM</given-names></name><name><surname>Parolin</surname><given-names>DA</given-names></name><name><surname>Lorimer</surname><given-names>IA</given-names></name></person-group><article-title>Regulation of glioblastoma cell invasion by PKC iota and RhoB</article-title><source>Oncogene</source><year>2008</year><volume>27</volume><fpage>3587</fpage><lpage>3595</lpage><pub-id pub-id-type="pmid">18212741</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1211027</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>R</given-names></name><name><surname>Win</surname><given-names>H</given-names></name><name><surname>Desai</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>K</given-names></name><name><surname>Matthews</surname><given-names>JA</given-names></name><name><surname>Acevedo-Duncan</surname><given-names>M</given-names></name></person-group><article-title>Involvement of PKC-iota in glioma proliferation</article-title><source>Cell Prolif</source><year>2008</year><volume>41</volume><fpage>122</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">18211289</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perletti</surname><given-names>GP</given-names></name><name><surname>Marras</surname><given-names>E</given-names></name><name><surname>Concari</surname><given-names>P</given-names></name><name><surname>Piccinini</surname><given-names>F</given-names></name><name><surname>Tashjian</surname><given-names>AH</given-names><suffix>Jr</suffix></name></person-group><article-title>PKCdelta acts as a growth and tumor suppressor in rat colonic epithelial cells</article-title><source>Oncogene</source><year>1999</year><volume>18</volume><fpage>1251</fpage><lpage>1256</lpage><pub-id pub-id-type="pmid">10022132</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1202408</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>AS</given-names></name><name><surname>West</surname><given-names>KA</given-names></name><name><surname>Blumberg</surname><given-names>PM</given-names></name><name><surname>Dennis</surname><given-names>PA</given-names></name></person-group><article-title>Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>780</fpage><lpage>786</lpage><pub-id pub-id-type="pmid">12591726</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCracken</surname><given-names>MA</given-names></name><name><surname>Miraglia</surname><given-names>LJ</given-names></name><name><surname>McKay</surname><given-names>RA</given-names></name><name><surname>Strobl</surname><given-names>JS</given-names></name></person-group><article-title>Protein kinase C delta is a prosurvival factor in human breast tumor cell lines</article-title><source>Mol Cancer Ther</source><year>2003</year><volume>2</volume><fpage>273</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">12657722</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mischak</surname><given-names>H</given-names></name><name><surname>Goodnight</surname><given-names>JA</given-names></name><name><surname>Kolch</surname><given-names>W</given-names></name><name><surname>Martiny-Baron</surname><given-names>G</given-names></name><name><surname>Schaechtle</surname><given-names>C</given-names></name><name><surname>Kazanietz</surname><given-names>MG</given-names></name><name><surname>Blumberg</surname><given-names>PM</given-names></name><name><surname>Pierce</surname><given-names>JH</given-names></name><name><surname>Mushinski</surname><given-names>JF</given-names></name></person-group><article-title>Overexpression of protein kinase C-delta and -epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity</article-title><source>J Biol Chem</source><year>1993</year><volume>268</volume><fpage>6090</fpage><lpage>6096</lpage><pub-id pub-id-type="pmid">8454583</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cacace</surname><given-names>AM</given-names></name><name><surname>Guadagno</surname><given-names>SN</given-names></name><name><surname>Krauss</surname><given-names>RS</given-names></name><name><surname>Fabbro</surname><given-names>D</given-names></name><name><surname>Weinstein</surname><given-names>IB</given-names></name></person-group><article-title>The epsilon isoform of protein kinase C is an oncogene when overexpressed in rat fibroblasts</article-title><source>Oncogene</source><year>1993</year><volume>8</volume><fpage>2095</fpage><lpage>2104</lpage><pub-id pub-id-type="pmid">8336936</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perletti</surname><given-names>GP</given-names></name><name><surname>Folini</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>HC</given-names></name><name><surname>Mischak</surname><given-names>H</given-names></name><name><surname>Piccinini</surname><given-names>F</given-names></name><name><surname>Tashjian</surname><given-names>AH</given-names><suffix>Jr</suffix></name></person-group><article-title>Overexpression of protein kinase C epsilon is oncogenic in rat colonic epithelial cells</article-title><source>Oncogene</source><year>1996</year><volume>12</volume><fpage>847</fpage><lpage>854</lpage><pub-id pub-id-type="pmid">8632907</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cacace</surname><given-names>AM</given-names></name><name><surname>Ueffing</surname><given-names>M</given-names></name><name><surname>Philipp</surname><given-names>A</given-names></name><name><surname>Han</surname><given-names>EK</given-names></name><name><surname>Kolch</surname><given-names>W</given-names></name><name><surname>Weinstein</surname><given-names>IB</given-names></name></person-group><article-title>PKC epsilon functions as an oncogene by enhancing activation of the Raf kinase</article-title><source>Oncogene</source><year>1996</year><volume>13</volume><fpage>2517</fpage><lpage>2526</lpage><pub-id pub-id-type="pmid">9000126</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>H</given-names></name><name><surname>Smola</surname><given-names>U</given-names></name><name><surname>Wixler</surname><given-names>V</given-names></name><name><surname>Eisenmann-Tappe</surname><given-names>I</given-names></name><name><surname>Diaz-Meco</surname><given-names>MT</given-names></name><name><surname>Moscat</surname><given-names>J</given-names></name><name><surname>Rapp</surname><given-names>U</given-names></name><name><surname>Cooper</surname><given-names>GM</given-names></name></person-group><article-title>Role of diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein kinase</article-title><source>Mol Cell Biol</source><year>1997</year><volume>17</volume><fpage>732</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">9001227</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ueffing</surname><given-names>M</given-names></name><name><surname>Lovric</surname><given-names>J</given-names></name><name><surname>Philipp</surname><given-names>A</given-names></name><name><surname>Mischak</surname><given-names>H</given-names></name><name><surname>Kolch</surname><given-names>W</given-names></name></person-group><article-title>Protein kinase C-epsilon associates with the Raf-1 kinase and induces the production of growth factors that stimulate Raf-1 activity</article-title><source>Oncogene</source><year>1997</year><volume>15</volume><fpage>2921</fpage><lpage>2927</lpage><pub-id pub-id-type="pmid">9416835</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1201477</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perletti</surname><given-names>GP</given-names></name><name><surname>Concari</surname><given-names>P</given-names></name><name><surname>Brusaferri</surname><given-names>S</given-names></name><name><surname>Marras</surname><given-names>E</given-names></name><name><surname>Piccinini</surname><given-names>F</given-names></name><name><surname>Tashjian</surname><given-names>AH</given-names><suffix>Jr</suffix></name></person-group><article-title>Protein kinase Cepsilon is oncogenic in colon epithelial cells by interaction with the ras signal transduction pathway</article-title><source>Oncogene</source><year>1998</year><volume>16</volume><fpage>3345</fpage><lpage>3348</lpage><pub-id pub-id-type="pmid">9681835</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1201871</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malumbres</surname><given-names>M</given-names></name><name><surname>Barbacid</surname><given-names>M</given-names></name></person-group><article-title>RAS oncogenes: the first 30 years</article-title><source>Nat Rev Cancer</source><year>2003</year><volume>3</volume><fpage>459</fpage><lpage>465</lpage><pub-id pub-id-type="pmid">12778136</pub-id><pub-id pub-id-type="doi">10.1038/nrc1097</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Albanese</surname><given-names>C</given-names></name><name><surname>Johnson</surname><given-names>J</given-names></name><name><surname>Watanabe</surname><given-names>G</given-names></name><name><surname>Eklund</surname><given-names>N</given-names></name><name><surname>Vu</surname><given-names>D</given-names></name><name><surname>Arnold</surname><given-names>A</given-names></name><name><surname>Pestell</surname><given-names>RG</given-names></name></person-group><article-title>Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions</article-title><source>J Biol Chem</source><year>1995</year><volume>270</volume><fpage>23589</fpage><lpage>23597</lpage><pub-id pub-id-type="pmid">7559524</pub-id><pub-id pub-id-type="doi">10.1074/jbc.270.40.23589</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lavoie</surname><given-names>JN</given-names></name><name><surname>Rivard</surname><given-names>N</given-names></name><name><surname>L'Allemain</surname><given-names>G</given-names></name><name><surname>Pouyssegur</surname><given-names>J</given-names></name></person-group><article-title>A temporal and biochemical link between growth factor-activated MAP kinases, cyclin D1 induction and cell cycle entry</article-title><source>Prog Cell Cycle Res</source><year>1996</year><volume>2</volume><fpage>49</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">9552382</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>JD</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Jefcoat</surname><given-names>SC</given-names><suffix>Jr</suffix></name><name><surname>Raben</surname><given-names>DM</given-names></name><name><surname>Baldassare</surname><given-names>JJ</given-names></name></person-group><article-title>Ras-stimulated extracellular signal-related kinase 1 and RhoA activities coordinate platelet-derived growth factor-induced G1 progression through the independent regulation of cyclin D1 and p27</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>32966</fpage><lpage>32971</lpage><pub-id pub-id-type="pmid">9407076</pub-id><pub-id pub-id-type="doi">10.1074/jbc.272.52.32966</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>M</given-names></name><name><surname>Sexl</surname><given-names>V</given-names></name><name><surname>Sherr</surname><given-names>CJ</given-names></name><name><surname>Roussel</surname><given-names>MF</given-names></name></person-group><article-title>Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1)</article-title><source>Proc Natl Acad Sci USA</source><year>1998</year><volume>95</volume><fpage>1091</fpage><lpage>1096</lpage><pub-id pub-id-type="pmid">9448290</pub-id><pub-id pub-id-type="doi">10.1073/pnas.95.3.1091</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kampfer</surname><given-names>S</given-names></name><name><surname>Windegger</surname><given-names>M</given-names></name><name><surname>Hochholdinger</surname><given-names>F</given-names></name><name><surname>Schwaiger</surname><given-names>W</given-names></name><name><surname>Pestell</surname><given-names>RG</given-names></name><name><surname>Baier</surname><given-names>G</given-names></name><name><surname>Grunicke</surname><given-names>HH</given-names></name><name><surname>Uberall</surname><given-names>F</given-names></name></person-group><article-title>Protein kinase C isoforms involved in the transcriptional activation of cyclin D1 by transforming Ha-Ras</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>42834</fpage><lpage>42842</lpage><pub-id pub-id-type="pmid">11551901</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M102047200</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Soh</surname><given-names>JW</given-names></name><name><surname>Weinstein</surname><given-names>IB</given-names></name></person-group><article-title>Roles of specific isoforms of protein kinase C in the transcriptional control of cyclin D1 and related genes</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>34709</fpage><lpage>34716</lpage><pub-id pub-id-type="pmid">12794082</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M302016200</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Lang</surname><given-names>W</given-names></name><name><surname>Xiao</surname><given-names>L</given-names></name></person-group><article-title>Protein kinase C-epsilon promotes survival of lung cancer cells by suppressing apoptosis through dysregulation of the mitochondrial caspase pathway</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>35305</fpage><lpage>35313</lpage><pub-id pub-id-type="pmid">12121973</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M201460200</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pardo</surname><given-names>OE</given-names></name><name><surname>Arcaro</surname><given-names>A</given-names></name><name><surname>Salerno</surname><given-names>G</given-names></name><name><surname>Raguz</surname><given-names>S</given-names></name><name><surname>Downward</surname><given-names>J</given-names></name><name><surname>Seckl</surname><given-names>MJ</given-names></name></person-group><article-title>Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>12040</fpage><lpage>12046</lpage><pub-id pub-id-type="pmid">11815602</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M109006200</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McJilton</surname><given-names>MA</given-names></name><name><surname>Van Sikes</surname><given-names>C</given-names></name><name><surname>Wescott</surname><given-names>GG</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Foreman</surname><given-names>TL</given-names></name><name><surname>Gregory</surname><given-names>CW</given-names></name><name><surname>Weidner</surname><given-names>DA</given-names></name><name><surname>Harris Ford</surname><given-names>O</given-names></name><name><surname>Morgan Lasater</surname><given-names>A</given-names></name><name><surname>Mohler</surname><given-names>JL</given-names></name><name><surname>Terrian</surname><given-names>DM</given-names></name></person-group><article-title>Protein kinase Cepsilon interacts with Bax and promotes survival of human prostate cancer cells</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>7958</fpage><lpage>7968</lpage><pub-id pub-id-type="pmid">12970744</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1206795</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pardo</surname><given-names>OE</given-names></name><name><surname>Lesay</surname><given-names>A</given-names></name><name><surname>Arcaro</surname><given-names>A</given-names></name><name><surname>Lopes</surname><given-names>R</given-names></name><name><surname>Ng</surname><given-names>BL</given-names></name><name><surname>Warne</surname><given-names>PH</given-names></name><name><surname>McNeish</surname><given-names>IA</given-names></name><name><surname>Tetley</surname><given-names>TD</given-names></name><name><surname>Lemoine</surname><given-names>NR</given-names></name><name><surname>Mehmet</surname><given-names>H</given-names></name><name><surname>Seckl</surname><given-names>MJ</given-names></name><name><surname>Downward</surname><given-names>J</given-names></name></person-group><article-title>Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cells</article-title><source>Mol Cell Biol</source><year>2003</year><volume>23</volume><fpage>7600</fpage><lpage>7610</lpage><pub-id pub-id-type="pmid">14560006</pub-id><pub-id pub-id-type="doi">10.1128/MCB.23.21.7600-7610.2003</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pardo</surname><given-names>OE</given-names></name><name><surname>Wellbrock</surname><given-names>C</given-names></name><name><surname>Khanzada</surname><given-names>UK</given-names></name><name><surname>Aubert</surname><given-names>M</given-names></name><name><surname>Arozarena</surname><given-names>I</given-names></name><name><surname>Davidson</surname><given-names>S</given-names></name><name><surname>Bowen</surname><given-names>F</given-names></name><name><surname>Parker</surname><given-names>PJ</given-names></name><name><surname>Filonenko</surname><given-names>VV</given-names></name><name><surname>Gout</surname><given-names>IT</given-names></name><name><surname>Sebire</surname><given-names>N</given-names></name><name><surname>Marais</surname><given-names>R</given-names></name><name><surname>Downward</surname><given-names>J</given-names></name><name><surname>Seckl</surname><given-names>MJ</given-names></name></person-group><article-title>FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2</article-title><source>EMBO J</source><year>2006</year><volume>25</volume><fpage>3078</fpage><lpage>3088</lpage><pub-id pub-id-type="pmid">16810323</pub-id><pub-id pub-id-type="doi">10.1038/sj.emboj.7601198</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>D</given-names></name><name><surname>Sivaprasad</surname><given-names>U</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Shankar</surname><given-names>E</given-names></name><name><surname>Morrow</surname><given-names>S</given-names></name><name><surname>Basu</surname><given-names>A</given-names></name></person-group><article-title>Protein kinase C-epsilon protects MCF-7 cells from TNF-mediated cell death by inhibiting Bax translocation</article-title><source>Apoptosis</source><year>2007</year><volume>12</volume><fpage>1893</fpage><lpage>1900</lpage><pub-id pub-id-type="pmid">17668322</pub-id><pub-id pub-id-type="doi">10.1007/s10495-007-0111-7</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sivaprasad</surname><given-names>U</given-names></name><name><surname>Shankar</surname><given-names>E</given-names></name><name><surname>Basu</surname><given-names>A</given-names></name></person-group><article-title>Downregulation of Bid is associated with PKCepsilon-mediated TRAIL resistance</article-title><source>Cell Death Differ</source><year>2007</year><volume>14</volume><fpage>851</fpage><lpage>860</lpage><pub-id pub-id-type="pmid">17186022</pub-id><pub-id pub-id-type="doi">10.1038/sj.cdd.4402077</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Thakore</surname><given-names>CU</given-names></name><name><surname>Wescott</surname><given-names>GG</given-names></name><name><surname>McCubrey</surname><given-names>JA</given-names></name><name><surname>Terrian</surname><given-names>DM</given-names></name></person-group><article-title>Integrin signaling links protein kinase Cepsilon to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>8659</fpage><lpage>8672</lpage><pub-id pub-id-type="pmid">15467757</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1207900</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okhrimenko</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Xiang</surname><given-names>C</given-names></name><name><surname>Hamburger</surname><given-names>N</given-names></name><name><surname>Kazimirsky</surname><given-names>G</given-names></name><name><surname>Brodie</surname><given-names>C</given-names></name></person-group><article-title>Protein kinase C-epsilon regulates the apoptosis and survival of glioma cells</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>7301</fpage><lpage>7309</lpage><pub-id pub-id-type="pmid">16103081</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1064</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Basu</surname><given-names>A</given-names></name></person-group><article-title>Protein kinase Cepsilon activates protein kinase B/Akt via DNA-PK to protect against tumor necrosis factor-alpha-induced cell death</article-title><source>J Biol Chem</source><year>2006</year><volume>281</volume><fpage>22799</fpage><lpage>22807</lpage><pub-id pub-id-type="pmid">16785234</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M603390200</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vivanco</surname><given-names>I</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name></person-group><article-title>The phosphatidylinositol 3-Kinase AKT pathway in human cancer</article-title><source>Nat Rev Cancer</source><year>2002</year><volume>2</volume><fpage>489</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">12094235</pub-id><pub-id pub-id-type="doi">10.1038/nrc839</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Basu</surname><given-names>A</given-names></name><name><surname>Sivaprasad</surname><given-names>U</given-names></name></person-group><article-title>Protein kinase Cepsilon makes the life and death decision</article-title><source>Cell Signal</source><year>2007</year><volume>19</volume><fpage>1633</fpage><lpage>1642</lpage><pub-id pub-id-type="pmid">17537614</pub-id><pub-id pub-id-type="doi">10.1016/j.cellsig.2007.04.008</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tachado</surname><given-names>SD</given-names></name><name><surname>Mayhew</surname><given-names>MW</given-names></name><name><surname>Wescott</surname><given-names>GG</given-names></name><name><surname>Foreman</surname><given-names>TL</given-names></name><name><surname>Goodwin</surname><given-names>CD</given-names></name><name><surname>McJilton</surname><given-names>MA</given-names></name><name><surname>Terrian</surname><given-names>DM</given-names></name></person-group><article-title>Regulation of tumor invasion and metastasis in protein kinase C epsilon-transformed NIH3T3 fibroblasts</article-title><source>J Cell Biochem</source><year>2002</year><volume>85</volume><fpage>785</fpage><lpage>797</lpage><pub-id pub-id-type="pmid">11968018</pub-id><pub-id pub-id-type="doi">10.1002/jcb.10164</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Bao</surname><given-names>LW</given-names></name><name><surname>Kleer</surname><given-names>CG</given-names></name><name><surname>Sabel</surname><given-names>MS</given-names></name><name><surname>Griffith</surname><given-names>KA</given-names></name><name><surname>Teknos</surname><given-names>TN</given-names></name><name><surname>Merajver</surname><given-names>SD</given-names></name></person-group><article-title>Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>8366</fpage><lpage>8371</lpage><pub-id pub-id-type="pmid">16166314</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-0553</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Bao</surname><given-names>LW</given-names></name><name><surname>Teknos</surname><given-names>TN</given-names></name><name><surname>Merajver</surname><given-names>SD</given-names></name></person-group><article-title>Targeted disruption of protein kinase C epsilon reduces cell invasion and motility through inactivation of RhoA and RhoC GTPases in head and neck squamous cell carcinoma</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>9379</fpage><lpage>9384</lpage><pub-id pub-id-type="pmid">17018591</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-2646</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prekeris</surname><given-names>R</given-names></name><name><surname>Hernandez</surname><given-names>RM</given-names></name><name><surname>Mayhew</surname><given-names>MW</given-names></name><name><surname>White</surname><given-names>MK</given-names></name><name><surname>Terrian</surname><given-names>DM</given-names></name></person-group><article-title>Molecular analysis of the interactions between protein kinase C-epsilon and filamentous actin</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><fpage>26790</fpage><lpage>26798</lpage><pub-id pub-id-type="pmid">9756923</pub-id><pub-id pub-id-type="doi">10.1074/jbc.273.41.26790</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hernandez</surname><given-names>RM</given-names></name><name><surname>Wescott</surname><given-names>GG</given-names></name><name><surname>Mayhew</surname><given-names>MW</given-names></name><name><surname>McJilton</surname><given-names>MA</given-names></name><name><surname>Terrian</surname><given-names>DM</given-names></name></person-group><article-title>Biochemical and morphogenic effects of the interaction between protein kinase C-epsilon and actin in vitro and in cultured NIH3T3 cells</article-title><source>J Cell Biochem</source><year>2001</year><volume>83</volume><fpage>532</fpage><lpage>546</lpage><pub-id pub-id-type="pmid">11746497</pub-id><pub-id pub-id-type="doi">10.1002/jcb.1246</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chun</surname><given-names>JS</given-names></name><name><surname>Ha</surname><given-names>MJ</given-names></name><name><surname>Jacobson</surname><given-names>BS</given-names></name></person-group><article-title>Differential translocation of protein kinase C epsilon during HeLa cell adhesion to a gelatin substratum</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>13008</fpage><lpage>13012</lpage><pub-id pub-id-type="pmid">8662811</pub-id><pub-id pub-id-type="doi">10.1074/jbc.271.22.13008</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berrier</surname><given-names>AL</given-names></name><name><surname>Mastrangelo</surname><given-names>AM</given-names></name><name><surname>Downward</surname><given-names>J</given-names></name><name><surname>Ginsberg</surname><given-names>M</given-names></name><name><surname>LaFlamme</surname><given-names>SE</given-names></name></person-group><article-title>Activated R-ras, Rac1, PI 3-kinase and PKCepsilon can each restore cell spreading inhibited by isolated integrin beta1 cytoplasmic domains</article-title><source>J Cell Biol</source><year>2000</year><volume>151</volume><fpage>1549</fpage><lpage>1560</lpage><pub-id pub-id-type="pmid">11134082</pub-id><pub-id pub-id-type="doi">10.1083/jcb.151.7.1549</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ivaska</surname><given-names>J</given-names></name><name><surname>Whelan</surname><given-names>RD</given-names></name><name><surname>Watson</surname><given-names>R</given-names></name><name><surname>Parker</surname><given-names>PJ</given-names></name></person-group><article-title>PKC epsilon controls the traffic of beta1 integrins in motile cells</article-title><source>EMBO J</source><year>2002</year><volume>21</volume><fpage>3608</fpage><lpage>3619</lpage><pub-id pub-id-type="pmid">12110574</pub-id><pub-id pub-id-type="doi">10.1093/emboj/cdf371</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ivaska</surname><given-names>J</given-names></name><name><surname>Vuoriluoto</surname><given-names>K</given-names></name><name><surname>Huovinen</surname><given-names>T</given-names></name><name><surname>Izawa</surname><given-names>I</given-names></name><name><surname>Inagaki</surname><given-names>M</given-names></name><name><surname>Parker</surname><given-names>PJ</given-names></name></person-group><article-title>PKCepsilon-mediated phosphorylation of vimentin controls integrin recycling and motility</article-title><source>EMBO J</source><year>2005</year><volume>24</volume><fpage>3834</fpage><lpage>3845</lpage><pub-id pub-id-type="pmid">16270034</pub-id><pub-id pub-id-type="doi">10.1038/sj.emboj.7600847</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Besson</surname><given-names>A</given-names></name><name><surname>Davy</surname><given-names>A</given-names></name><name><surname>Robbins</surname><given-names>SM</given-names></name><name><surname>Yong</surname><given-names>VW</given-names></name></person-group><article-title>Differential activation of ERKs to focal adhesions by PKC epsilon is required for PMA-induced adhesion and migration of human glioma cells</article-title><source>Oncogene</source><year>2001</year><volume>20</volume><fpage>7398</fpage><lpage>7407</lpage><pub-id pub-id-type="pmid">11704869</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1204899</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Besson</surname><given-names>A</given-names></name><name><surname>Wilson</surname><given-names>TL</given-names></name><name><surname>Yong</surname><given-names>VW</given-names></name></person-group><article-title>The anchoring protein RACK1 links protein kinase Cepsilon to integrin beta chains. Requirements for adhesion and motility</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>22073</fpage><lpage>22084</lpage><pub-id pub-id-type="pmid">11934885</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M111644200</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Baines</surname><given-names>CP</given-names></name><name><surname>Zong</surname><given-names>C</given-names></name><name><surname>Cardwell</surname><given-names>EM</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Vondriska</surname><given-names>TM</given-names></name><name><surname>Ping</surname><given-names>P</given-names></name></person-group><article-title>Functional proteomic analysis of a three-tier PKCepsilon-Akt-eNOS signaling module in cardiac protection</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2005</year><volume>288</volume><fpage>H954</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">15528226</pub-id><pub-id pub-id-type="doi">10.1152/ajpheart.00756.2004</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>GL</given-names></name><name><surname>Zhuo</surname><given-names>Y</given-names></name><name><surname>King</surname><given-names>CC</given-names></name><name><surname>Fryer</surname><given-names>BH</given-names></name><name><surname>Bokoch</surname><given-names>GM</given-names></name><name><surname>Field</surname><given-names>J</given-names></name></person-group><article-title>Akt phosphorylation of serine 21 on Pak1 modulates Nck binding and cell migration</article-title><source>Mol Cell Biol</source><year>2003</year><volume>23</volume><fpage>8058</fpage><lpage>8069</lpage><pub-id pub-id-type="pmid">14585966</pub-id><pub-id pub-id-type="doi">10.1128/MCB.23.22.8058-8069.2003</pub-id></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Menard</surname><given-names>RE</given-names></name><name><surname>Mattingly</surname><given-names>RR</given-names></name></person-group><article-title>Gbetagamma subunits stimulate p21-activated kinase 1 (PAK1) through activation of PI3-kinase and Akt but act independently of Rac1/Cdc42</article-title><source>FEBS Lett</source><year>2004</year><volume>556</volume><fpage>187</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">14706848</pub-id><pub-id pub-id-type="doi">10.1016/S0014-5793(03)01406-6</pub-id></citation></ref><ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alberts</surname><given-names>AS</given-names></name><name><surname>Qin</surname><given-names>H</given-names></name><name><surname>Carr</surname><given-names>HS</given-names></name><name><surname>Frost</surname><given-names>JA</given-names></name></person-group><article-title>PAK1 negatively regulates the activity of the Rho exchange factor NET1</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>12152</fpage><lpage>12161</lpage><pub-id pub-id-type="pmid">15684429</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M405073200</pub-id></citation></ref><ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>LC</given-names></name><name><surname>Matsumura</surname><given-names>F</given-names></name><name><surname>Bokoch</surname><given-names>GM</given-names></name><name><surname>de Lanerolle</surname><given-names>P</given-names></name></person-group><article-title>Inhibition of myosin light chain kinase by p21-activated kinase</article-title><source>Science</source><year>1999</year><volume>283</volume><fpage>2083</fpage><lpage>2085</lpage><pub-id pub-id-type="pmid">10092231</pub-id><pub-id pub-id-type="doi">10.1126/science.283.5410.2083</pub-id></citation></ref><ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ikebe</surname><given-names>M</given-names></name><name><surname>Hartshorne</surname><given-names>DJ</given-names></name></person-group><article-title>Phosphorylation of smooth muscle myosin at two distinct sites by myosin light chain kinase</article-title><source>J Biol Chem</source><year>1985</year><volume>260</volume><fpage>10027</fpage><lpage>10031</lpage><pub-id pub-id-type="pmid">3839510</pub-id></citation></ref><ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Totsukawa</surname><given-names>G</given-names></name><name><surname>Yamakita</surname><given-names>Y</given-names></name><name><surname>Yamashiro</surname><given-names>S</given-names></name><name><surname>Hartshorne</surname><given-names>DJ</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Matsumura</surname><given-names>F</given-names></name></person-group><article-title>Distinct roles of ROCK (Rho-kinase) and MLCK in spatial regulation of MLC phosphorylation for assembly of stress fibers and focal adhesions in 3T3 fibroblasts</article-title><source>J Cell Biol</source><year>2000</year><volume>150</volume><fpage>797</fpage><lpage>806</lpage><pub-id pub-id-type="pmid">10953004</pub-id><pub-id pub-id-type="doi">10.1083/jcb.150.4.797</pub-id></citation></ref><ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>DC</given-names></name><name><surname>Sanders</surname><given-names>LC</given-names></name><name><surname>Bokoch</surname><given-names>GM</given-names></name><name><surname>Gill</surname><given-names>GN</given-names></name></person-group><article-title>Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics</article-title><source>Nat Cell Biol</source><year>1999</year><volume>1</volume><fpage>253</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">10559936</pub-id><pub-id pub-id-type="doi">10.1038/12963</pub-id></citation></ref><ref id="B63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sumi</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name></person-group><article-title>Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROCK, a Rho-dependent protein kinase</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>670</fpage><lpage>676</lpage><pub-id pub-id-type="pmid">11018042</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M007074200</pub-id></citation></ref><ref id="B64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maekawa</surname><given-names>M</given-names></name><name><surname>Ishizaki</surname><given-names>T</given-names></name><name><surname>Boku</surname><given-names>S</given-names></name><name><surname>Watanabe</surname><given-names>N</given-names></name><name><surname>Fujita</surname><given-names>A</given-names></name><name><surname>Iwamatsu</surname><given-names>A</given-names></name><name><surname>Obinata</surname><given-names>T</given-names></name><name><surname>Ohashi</surname><given-names>K</given-names></name><name><surname>Mizuno</surname><given-names>K</given-names></name><name><surname>Narumiya</surname><given-names>S</given-names></name></person-group><article-title>Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase</article-title><source>Science</source><year>1999</year><volume>285</volume><fpage>895</fpage><lpage>898</lpage><pub-id pub-id-type="pmid">10436159</pub-id><pub-id pub-id-type="doi">10.1126/science.285.5429.895</pub-id></citation></ref><ref id="B65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amano</surname><given-names>T</given-names></name><name><surname>Tanabe</surname><given-names>K</given-names></name><name><surname>Eto</surname><given-names>T</given-names></name><name><surname>Narumiya</surname><given-names>S</given-names></name><name><surname>Mizuno</surname><given-names>K</given-names></name></person-group><article-title>LIM-kinase 2 induces formation of stress fibres, focal adhesions and membrane blebs, dependent on its activation by Rho-associated kinase-catalysed phosphorylation at threonine-505</article-title><source>Biochem J</source><year>2001</year><volume>354</volume><fpage>149</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">11171090</pub-id><pub-id pub-id-type="doi">10.1042/0264-6021:3540149</pub-id></citation></ref><ref id="B66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aziz</surname><given-names>MH</given-names></name><name><surname>Manoharan</surname><given-names>HT</given-names></name><name><surname>Sand</surname><given-names>JM</given-names></name><name><surname>Verma</surname><given-names>AK</given-names></name></person-group><article-title>Protein kinase Cepsilon interacts with Stat3 and regulates its activation that is essential for the development of skin cancer</article-title><source>Mol Carcinog</source><year>2007</year><volume>46</volume><fpage>646</fpage><lpage>653</lpage><pub-id pub-id-type="pmid">17583567</pub-id><pub-id pub-id-type="doi">10.1002/mc.20356</pub-id></citation></ref><ref id="B67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aziz</surname><given-names>MH</given-names></name><name><surname>Manoharan</surname><given-names>HT</given-names></name><name><surname>Church</surname><given-names>DR</given-names></name><name><surname>Dreckschmidt</surname><given-names>NE</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Oberley</surname><given-names>TD</given-names></name><name><surname>Wilding</surname><given-names>G</given-names></name><name><surname>Verma</surname><given-names>AK</given-names></name></person-group><article-title>Protein kinase Cepsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>8828</fpage><lpage>8838</lpage><pub-id pub-id-type="pmid">17875724</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-1604</pub-id></citation></ref><ref id="B68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aziz</surname><given-names>MH</given-names></name><name><surname>Manoharan</surname><given-names>HT</given-names></name><name><surname>Verma</surname><given-names>AK</given-names></name></person-group><article-title>Protein kinase C epsilon, which sensitizes skin to sun's UV radiation-induced cutaneous damage and development of squamous cell carcinomas, associates with Stat3</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>1385</fpage><lpage>1394</lpage><pub-id pub-id-type="pmid">17283176</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3350</pub-id></citation></ref><ref id="B69"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Debidda</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zang</surname><given-names>H</given-names></name><name><surname>Poli</surname><given-names>V</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name></person-group><article-title>A role of STAT3 in Rho GTPase-regulated cell migration and proliferation</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>17275</fpage><lpage>17285</lpage><pub-id pub-id-type="pmid">15705584</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M413187200</pub-id></citation></ref><ref id="B70"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>DC</given-names></name><name><surname>Lin</surname><given-names>BH</given-names></name><name><surname>Lim</surname><given-names>CP</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Poli</surname><given-names>V</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name></person-group><article-title>Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin</article-title><source>J Cell Biol</source><year>2006</year><volume>172</volume><fpage>245</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">16401721</pub-id><pub-id pub-id-type="doi">10.1083/jcb.200503021</pub-id></citation></ref><ref id="B71"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beretta</surname><given-names>L</given-names></name><name><surname>Dobransky</surname><given-names>T</given-names></name><name><surname>Sobel</surname><given-names>A</given-names></name></person-group><article-title>Multiple phosphorylation of stathmin. Identification of four sites phosphorylated in intact cells and in vitro by cyclic AMP-dependent protein kinase and p34cdc2</article-title><source>J Biol Chem</source><year>1993</year><volume>268</volume><fpage>20076</fpage><lpage>20084</lpage><pub-id pub-id-type="pmid">8376365</pub-id></citation></ref><ref id="B72"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leighton</surname><given-names>IA</given-names></name><name><surname>Curmi</surname><given-names>P</given-names></name><name><surname>Campbell</surname><given-names>DG</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name><name><surname>Sobel</surname><given-names>A</given-names></name></person-group><article-title>The phosphorylation of stathmin by MAP kinase</article-title><source>Mol Cell Biochem</source><year>1993</year><volume>127&#x02013;128</volume><fpage>151</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">7935347</pub-id><pub-id pub-id-type="doi">10.1007/BF01076766</pub-id></citation></ref><ref id="B73"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Honnappa</surname><given-names>S</given-names></name><name><surname>Jahnke</surname><given-names>W</given-names></name><name><surname>Seelig</surname><given-names>J</given-names></name><name><surname>Steinmetz</surname><given-names>MO</given-names></name></person-group><article-title>Control of intrinsically disordered stathmin by multisite phosphorylation</article-title><source>J Biol Chem</source><year>2006</year><volume>281</volume><fpage>16078</fpage><lpage>16083</lpage><pub-id pub-id-type="pmid">16554300</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M513524200</pub-id></citation></ref><ref id="B74"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Collisson</surname><given-names>EA</given-names></name><name><surname>Kleer</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>De</surname><given-names>A</given-names></name><name><surname>Gambhir</surname><given-names>SS</given-names></name><name><surname>Merajver</surname><given-names>SD</given-names></name><name><surname>Kolodney</surname><given-names>MS</given-names></name></person-group><article-title>Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells</article-title><source>Mol Cancer Ther</source><year>2003</year><volume>2</volume><fpage>941</fpage><lpage>948</lpage><pub-id pub-id-type="pmid">14578459</pub-id></citation></ref><ref id="B75"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>HW</given-names></name><name><surname>Halayko</surname><given-names>AJ</given-names></name><name><surname>Fernandes</surname><given-names>DJ</given-names></name><name><surname>Harmon</surname><given-names>GS</given-names></name><name><surname>McCauley</surname><given-names>JA</given-names></name><name><surname>Kocieniewski</surname><given-names>P</given-names></name><name><surname>McConville</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Forsythe</surname><given-names>SM</given-names></name><name><surname>Kogut</surname><given-names>P</given-names></name><name><surname>Bellam</surname><given-names>S</given-names></name><name><surname>Dowell</surname><given-names>M</given-names></name><name><surname>Churchill</surname><given-names>J</given-names></name><name><surname>Lesso</surname><given-names>H</given-names></name><name><surname>Kassiri</surname><given-names>K</given-names></name><name><surname>Mitchell</surname><given-names>RW</given-names></name><name><surname>Hershenson</surname><given-names>MB</given-names></name><name><surname>Camoretti-Mercado</surname><given-names>B</given-names></name><name><surname>Solway</surname><given-names>J</given-names></name></person-group><article-title>The RhoA/Rho kinase pathway regulates nuclear localization of serum response factor</article-title><source>Am J Respir Cell Mol Biol</source><year>2003</year><volume>29</volume><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">12600823</pub-id><pub-id pub-id-type="doi">10.1165/rcmb.2002-0206OC</pub-id></citation></ref><ref id="B76"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Knauf</surname><given-names>JA</given-names></name><name><surname>Gonsky</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Lai</surname><given-names>EH</given-names></name><name><surname>Chissoe</surname><given-names>S</given-names></name><name><surname>Fagin</surname><given-names>JA</given-names></name><name><surname>Korenberg</surname><given-names>JR</given-names></name></person-group><article-title>From amplification to gene in thyroid cancer: a high-resolution mapped bacterial-artificial-chromosome resource for cancer chromosome aberrations guides gene discovery after comparative genome hybridization</article-title><source>Am J Hum Genet</source><year>1998</year><volume>63</volume><fpage>625</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">9683604</pub-id><pub-id pub-id-type="doi">10.1086/301973</pub-id></citation></ref><ref id="B77"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knauf</surname><given-names>JA</given-names></name><name><surname>Elisei</surname><given-names>R</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name><name><surname>Liron</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>XN</given-names></name><name><surname>Gonsky</surname><given-names>R</given-names></name><name><surname>Korenberg</surname><given-names>JR</given-names></name><name><surname>Fagin</surname><given-names>JA</given-names></name></person-group><article-title>Involvement of protein kinase Cepsilon (PKCepsilon) in thyroid cell death. A truncated chimeric PKCepsilon cloned from a thyroid cancer cell line protects thyroid cells from apoptosis</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>23414</fpage><lpage>23425</lpage><pub-id pub-id-type="pmid">10438519</pub-id><pub-id pub-id-type="doi">10.1074/jbc.274.33.23414</pub-id></citation></ref><ref id="B78"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Gimeno</surname><given-names>C</given-names></name><name><surname>Diaz-Meco</surname><given-names>MT</given-names></name><name><surname>Dominguez</surname><given-names>I</given-names></name><name><surname>Moscat</surname><given-names>J</given-names></name></person-group><article-title>Alterations in levels of different protein kinase C isotypes and their influence on behavior of squamous cell carcinoma of the oral cavity: epsilon PKC, a novel prognostic factor for relapse and survival</article-title><source>Head Neck</source><year>1995</year><volume>17</volume><fpage>516</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">8847210</pub-id><pub-id pub-id-type="doi">10.1002/hed.2880170609</pub-id></citation></ref><ref id="B79"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baxter</surname><given-names>G</given-names></name><name><surname>Oto</surname><given-names>E</given-names></name><name><surname>Daniel-Issakani</surname><given-names>S</given-names></name><name><surname>Strulovici</surname><given-names>B</given-names></name></person-group><article-title>Constitutive presence of a catalytic fragment of protein kinase C epsilon in a small cell lung carcinoma cell line</article-title><source>J Biol Chem</source><year>1992</year><volume>267</volume><fpage>1910</fpage><lpage>1917</lpage><pub-id pub-id-type="pmid">1309802</pub-id></citation></ref><ref id="B80"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>KM</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>MG</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Xiao</surname><given-names>L</given-names></name></person-group><article-title>Protein kinase C epsilon is overexpressed in primary human non-small cell lung cancers and functionally required for proliferation of non-small cell lung cancer cells in a p21/Cip1-dependent manner</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>6053</fpage><lpage>6063</lpage><pub-id pub-id-type="pmid">17616661</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-4037</pub-id></citation></ref><ref id="B81"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Foreman</surname><given-names>TL</given-names></name><name><surname>Gregory</surname><given-names>CW</given-names></name><name><surname>McJilton</surname><given-names>MA</given-names></name><name><surname>Wescott</surname><given-names>GG</given-names></name><name><surname>Ford</surname><given-names>OH</given-names></name><name><surname>Alvey</surname><given-names>RF</given-names></name><name><surname>Mohler</surname><given-names>JL</given-names></name><name><surname>Terrian</surname><given-names>DM</given-names></name></person-group><article-title>Protein kinase cepsilon has the potential to advance the recurrence of human prostate cancer</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><fpage>2423</fpage><lpage>2429</lpage><pub-id pub-id-type="pmid">11956106</pub-id></citation></ref><ref id="B82"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cornford</surname><given-names>P</given-names></name><name><surname>Evans</surname><given-names>J</given-names></name><name><surname>Dodson</surname><given-names>A</given-names></name><name><surname>Parsons</surname><given-names>K</given-names></name><name><surname>Woolfenden</surname><given-names>A</given-names></name><name><surname>Neoptolemos</surname><given-names>J</given-names></name><name><surname>Foster</surname><given-names>CS</given-names></name></person-group><article-title>Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer</article-title><source>Am J Pathol</source><year>1999</year><volume>154</volume><fpage>137</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">9916928</pub-id></citation></ref><ref id="B83"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>W</given-names></name><name><surname>Benzing</surname><given-names>F</given-names></name><name><surname>Gudejko-Thiel</surname><given-names>J</given-names></name><name><surname>Fischer</surname><given-names>R</given-names></name><name><surname>Farber</surname><given-names>G</given-names></name><name><surname>Hengstler</surname><given-names>JG</given-names></name><name><surname>Seliger</surname><given-names>B</given-names></name><name><surname>Thuroff</surname><given-names>JW</given-names></name></person-group><article-title>Regulation of beta1 integrin expression by PKCepsilon in renal cancer cells</article-title><source>Int J Oncol</source><year>2004</year><volume>25</volume><fpage>1157</fpage><lpage>1163</lpage><pub-id pub-id-type="pmid">15375568</pub-id></citation></ref><ref id="B84"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Varga</surname><given-names>A</given-names></name><name><surname>Czifra</surname><given-names>G</given-names></name><name><surname>Tallai</surname><given-names>B</given-names></name><name><surname>Nemeth</surname><given-names>T</given-names></name><name><surname>Kovacs</surname><given-names>I</given-names></name><name><surname>Kovacs</surname><given-names>L</given-names></name><name><surname>Biro</surname><given-names>T</given-names></name></person-group><article-title>Tumor grade-dependent alterations in the protein kinase C isoform pattern in urinary bladder carcinomas</article-title><source>Eur Urol</source><year>2004</year><volume>46</volume><fpage>462</fpage><lpage>465</lpage><pub-id pub-id-type="pmid">15363561</pub-id></citation></ref><ref id="B85"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wheeler</surname><given-names>DL</given-names></name><name><surname>Martin</surname><given-names>KE</given-names></name><name><surname>Ness</surname><given-names>KJ</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Dreckschmidt</surname><given-names>NE</given-names></name><name><surname>Wartman</surname><given-names>M</given-names></name><name><surname>Ananthaswamy</surname><given-names>HN</given-names></name><name><surname>Mitchell</surname><given-names>DL</given-names></name><name><surname>Verma</surname><given-names>AK</given-names></name></person-group><article-title>Protein kinase C epsilon is an endogenous photosensitizer that enhances ultraviolet radiation-induced cutaneous damage and development of squamous cell carcinomas</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>7756</fpage><lpage>7765</lpage><pub-id pub-id-type="pmid">15520180</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1881</pub-id></citation></ref><ref id="B86"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Goldthwait</surname><given-names>DA</given-names></name><name><surname>Mapstone</surname><given-names>T</given-names></name></person-group><article-title>The identification of four protein kinase C isoforms in human glioblastoma cell lines: PKC alpha, gamma, epsilon, and zeta</article-title><source>J Neurosurg</source><year>1994</year><volume>81</volume><fpage>734</fpage><lpage>740</lpage><pub-id pub-id-type="pmid">7931620</pub-id></citation></ref><ref id="B87"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sharif</surname><given-names>TR</given-names></name><name><surname>Sharif</surname><given-names>M</given-names></name></person-group><article-title>Overexpression of protein kinase C epsilon in astroglial brain tumor derived cell lines and primary tumor samples</article-title><source>Int J Oncol</source><year>1999</year><volume>15</volume><fpage>237</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">10402232</pub-id></citation></ref><ref id="B88"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wheeler</surname><given-names>DL</given-names></name><name><surname>Reddig</surname><given-names>PJ</given-names></name><name><surname>Ness</surname><given-names>KJ</given-names></name><name><surname>Leith</surname><given-names>CP</given-names></name><name><surname>Oberley</surname><given-names>TD</given-names></name><name><surname>Verma</surname><given-names>AK</given-names></name></person-group><article-title>Overexpression of protein kinase C-{epsilon} in the mouse epidermis leads to a spontaneous myeloproliferative-like disease</article-title><source>Am J Pathol</source><year>2005</year><volume>166</volume><fpage>117</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">15632005</pub-id></citation></ref></ref-list></back></article>